GlaxoSmithKline announced comprehensive plans to invest $30 billion over five years to bolster U.S.-based drug manufacturing capabilities and research infrastructure. The initiative includes building biologics facilities, upgrading existing plants, and supporting clinical trials to strengthen the company’s position in its largest market. This commitment reflects broader pharma industry trends responding to geopolitical and economic pressures, emphasizing reshoring efforts and innovation leadership. GSK cites alignment with U.S. policy priorities and aims to maintain competitive edge through significant domestic investments.